Fuse Medical Inc (FZMD) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Fuse Medical Inc $0.03, price $0.03, upside -9.0%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Fuse Medical Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $0.0200 – $0.8000 · fair‑value band $0.0250 – $0.0291 · the $0.0300 price screens above the $0.0273 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Fuse Medical in your weekly email
Every Wednesday you see whether Fuse Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Fuse Medical, Inc. manufactures and distributes medical devices in the United States.
Show more
Fuse Medical, Inc. manufactures and distributes medical devices in the United States. The company provides orthopedic implants, including internal and external fixation products; upper and lower extremity plating and total joint reconstruction implants; soft tissue fixation and augmentation for sports medicine procedures; and full spinal implants for trauma, degenerative disc disease, and deformity indications. It also provides osteo-biologics and regenerative products, which include human allografts, tendons, substitute bone materials, and regenerative tissues. The company serves hospitals, medical facilities, and sub-distributors. Fuse Medical, Inc. is based in Farmers Branch, Texas.
Stock analysis
Fuse Medical Inc (FZMD) currently trades at $0.0300, while our model-based Fair Value estimate is $0.0273, implying the stock looks roughly 9.9% fairly valued today.
Show more
Valuation
Bull case: the Earnings-Based group reads highest at a median of $0.2400 per share, and 15 of the 15 models we run sit above the $0.0300 price.
Bear case: the Asset-Based group reads lowest at $0.0600, and 0 of the 15 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.0250 (bear) to $0.0291 (bull), the price of $0.0300 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Spin-off in 2024: revenue and profit before it include the divested business. Growth is measured afresh from 2024.
Fuse Medical Inc reported revenue of $10.7M in FY2024 versus $21.4M in FY2020, a compound −15.9%/yr. Reported net income was $514K in FY2024.
Key figures
Market cap $2.3M · P/E ratio 1.5 · P/S ratio 0.07 · EPS (TTM) $0.0200 · Net margin 4.8% · Return on assets (EBIT) −2.9% · Operating margin 7.4% · Revenue (TTM) $18.4M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 70% below its 52-week high and 50% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −9%, FZMD screens richer than that median.
Fair Value models
Bear $0.0250Fair Value $0.0273Bull $0.0291
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2024 figures (about 12 months old). Earnings retained since then ($0.0200 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Spin-off in 2024: revenue and profit before it include the divested business. Growth is measured afresh from 2024.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.4%
Revenue growth 37 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.2%
’13
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−34.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−34.2%
Dividend (yield on the price)0.0%
Profit margin 2019 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−15% → 7%
⚠ Revenue per share shrinking 7.3%/yr over ~16Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks
Beats the industry median on 9/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score44 · Below median
Fair Value upside−9% · Above median
Profitability
Return on assets0% · Below median
Net margin (TTM)22% · Top 25%
Operating margin (TTM)7% · Above median
Growth and dividend
Revenue growth7% · Above median
Balance sheet
Debt / equity0.03× · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Fuse Medical Inc Fair Value". https://www.fairvalue-calculator.com/stock/FZMD
Frequently asked questions
Is Fuse Medical Inc (FZMD) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.0273 versus a price of $0.0300, about −9% upside (fairly valued).
What is the fair value of FZMD?
Our model-based fair value for Fuse Medical Inc is $0.0273 (as of Sep 23, 2026), built from audited fundamentals. The current price: $0.0300.
What is the quality score of FZMD?
Fuse Medical Inc has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Fuse Medical Inc (FZMD)?
Our model-based price target is the fair value of $0.0273 (as of Sep 23, 2026) from 15 valuation models. Cautious scenario $0.0250, optimistic scenario $0.0291. It is a calculation from audited fundamentals, not an analyst target.
What is the Fuse Medical Inc stock forecast for 2026?
Our models put fair value at $0.0273, about −9% upside versus a price of $0.0300 (fairly valued). Cautious scenario $0.0250, optimistic scenario $0.0291. The calculation is refreshed regularly with new filings.
What is the revenue of Fuse Medical Inc (FZMD)?
Fuse Medical Inc reported trailing-twelve-month revenue of about $18.4M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Fuse Medical Inc (FZMD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Fuse Medical Inc it is $0.0273 per share (as of Sep 23, 2026), against a price of $0.0300. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Fuse Medical Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, FZMD trades above its calculated fair value: price $0.0300, fair value $0.0273, a gap of about −9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of FZMD?
No. The price is what the market pays today ($0.0300); the fair value is what the company's own numbers justify ($0.0273). For Fuse Medical Inc the two are $0.0027 per share apart. That gap is exactly why we show both numbers side by side.
How much is Fuse Medical Inc worth?
The market values Fuse Medical Inc at about $2.3M (market capitalisation, as of Sep 23, 2026). Per share that is $0.0300; our models calculate a fair value of $0.0273 per share.
What do the bullish and bearish scenarios say about FZMD?
Our models span a range for Fuse Medical Inc: cautious scenario $0.0250, base $0.0273, optimistic $0.0291 per share (as of Sep 23, 2026, price $0.0300). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of FZMD?
Fuse Medical Inc trades at a price-to-earnings ratio of 1.5 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.0273 is built from several models across several years. Other multiples: P/B 0.4, P/S 0.1, EV/EBITDA 9.6.
How solid is the balance sheet of Fuse Medical Inc (FZMD)?
Balance-sheet figures for Fuse Medical Inc (as of Sep 23, 2026): debt of 0.03 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is FZMD from its 52-week high?
Fuse Medical Inc trades at $0.0300, about 70% below its 52-week high of $0.1000 and 50% above the low of $0.0200 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0273 is for.
Which stocks are comparable to Fuse Medical Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Fuse Medical Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $0.0300, calculated fair value $0.0273 (−9%), Quality Score 44/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of FZMD calculated?
We run Fuse Medical Inc through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0273, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Fuse Medical Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Fuse Medical Inc (FZMD)?
The closing price on Sep 23, 2026 was $0.0300. Our model-based fair value is $0.0273, about −9% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Fuse Medical Inc right now?
The price sits above even our optimistic bull case ($0.0291). The favourable scenario is already priced in. The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Fuse Medical Inc
How large is the market capitalisation of Fuse Medical Inc (FZMD)?
The market capitalisation of Fuse Medical Inc is $2.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Fuse Medical Inc (FZMD)?
The price-to-sales ratio of Fuse Medical Inc is 0.07 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Fuse Medical Inc (FZMD)?
Earnings per share at Fuse Medical Inc are $0.0200 (price ÷ EPS = P/E 1.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Fuse Medical Inc (FZMD)?
The net margin of Fuse Medical Inc is 4.8% (fiscal year 2024). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Fuse Medical Inc (FZMD)?
On an EBIT basis the return on assets of Fuse Medical Inc is −2.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Fuse Medical Inc (FZMD)?
The operating margin of Fuse Medical Inc is 7.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Fuse Medical Inc (FZMD)?
Revenue at Fuse Medical Inc is growing +7.0% versus a year earlier (3y avg −19.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Fuse Medical Inc (FZMD)?
Earnings per share at Fuse Medical Inc are growing −71.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Fuse Medical Inc (FZMD) generate?
The free cash flow of Fuse Medical Inc is −$219K (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Fuse Medical Inc (FZMD) carry?
The net debt of Fuse Medical Inc is $2.0M (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Fuse Medical Inc in the live analysis
One click puts Fuse Medical Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026